
A large, ambitious contrast of blood-thinning medications used during cardiac stent placement suggests that a very expensive drug offers no clear safety benefits over a much more affordable option, according to a researcher and cardiologist.
http://www.sciencedaily.com/releases/2015/09/150901100321.htm